Celltrion’s Remicade Biosimilar Takes U.S. Regulatory Shortcuts
This article was originally published in PharmAsia News
Executive Summary
After just one year of working with the U.S FDA, the South Korean company is positioning itself to launch its first monoclonal antibody biosimilar in the U.S. market.